Related references
Note: Only part of the references are listed.ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3
Lijie Zhou et al.
THERANOSTICS (2021)
Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer
Qi Cao et al.
CLINICAL CANCER RESEARCH (2020)
Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer
Michihiko Kuwano et al.
CANCER SCIENCE (2019)
SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer
Zhen Tao et al.
CLINICAL CANCER RESEARCH (2019)
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
A. R. Hansen et al.
ANNALS OF ONCOLOGY (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Overexpression of SOX4 promotes cell migration and invasion of renal cell carcinoma by inducing epithelial-mesenchymal transition
Hailong Ruan et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Tomasz M. Beer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Immunotherapy of Prostate Cancer: Facts and Hopes
Marijo Bilusic et al.
CLINICAL CANCER RESEARCH (2017)
Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling
Tao Wang et al.
CLINICAL CANCER RESEARCH (2016)
Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT-YB1-MDR1 Signaling Pathway
Dongliang Mo et al.
CANCER RESEARCH (2016)
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
Akash Kumar et al.
NATURE MEDICINE (2016)
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
Julie N. Graff et al.
ONCOTARGET (2016)
Flightless-1, a novel transcriptional modulator of PPAR gamma through competing with RXR alpha
Jin Sil Choi et al.
CELLULAR SIGNALLING (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
A. M. Martin et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2015)
Immune Checkpoint Protein Inhibition for Cancer: Preclinical Justification for CTLA-4 and PD-1 Blockade and New Combinations
Kathryn Baksh et al.
SEMINARS IN ONCOLOGY (2015)
The environment of regulatory T cell biology: cytokines, metabolites, and the microbiome
Romy E. Hoeppli et al.
FRONTIERS IN IMMUNOLOGY (2015)
Androgens and androgen receptor signaling in prostate tumorigenesis
Ye Zhou et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2015)
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
Jennifer L. Bishop et al.
ONCOTARGET (2015)
Nivolumab: Promising Survival Signal Coupled With Limited Toxicity Raises Expectations
Geraldine O'Sullivan Coyne et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al.
LANCET ONCOLOGY (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Control of the adaptive immune response by tumor vasculature
Laetitia Mauge et al.
FRONTIERS IN ONCOLOGY (2014)
Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer
Jaikumar Duraiswamy et al.
CANCER RESEARCH (2013)
Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
Jaikumar Duraiswamy et al.
CANCER RESEARCH (2013)
The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells
Dennis Lindau et al.
IMMUNOLOGY (2013)
Flightless I homolog negatively regulates ChREBP activity in cancer cells
Lifang Wu et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines
Serges P. Tsofack et al.
MOLECULAR CANCER (2011)
The genomic complexity of primary human prostate cancer
Michael F. Berger et al.
NATURE (2011)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
Prostate cancer as a model for tumour immunotherapy
Charles G. Drake
NATURE REVIEWS IMMUNOLOGY (2010)
Interplay of Fli-I and FLAP1 for regulation of β-catenin dependent transcription
Young-Ho Lee et al.
NUCLEIC ACIDS RESEARCH (2006)
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
C Blank et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Developmentally essential protein flightless I is a nuclear receptor coactivator with actin binding activity
YH Lee et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Blockade of programmed death-1 Ligands on dendritic cells enhances T cell activation and cytokine production
JA Brown et al.
JOURNAL OF IMMUNOLOGY (2003)
Share Paper
